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There are conﬂicting studies on T cell cytokine production in childhood asthma. In this study intracellular cytokine expression
of IL-2, IL-4, IL-10, IL-13, IFN-γ,a n dT N F - α in CD4+ and CD8+ T cells in children with atopic asthma were measured by ﬂow
cytometry. Results. Asigniﬁcantincreasein thepercentage ofCD4+ andCD8+ Tc e l l sp r od u c i ngI L - 4andI L - 1 3andd e c r e asei nt h e
percentage of CD4+ producing IFN-γ in asthmaticchildren was found. The percentage of CD4+/IL-13+ was signiﬁcantlyhigher in
severe asthma than in children with intermittent disease symptoms. Severity of asthma was associated with increased both serum
IgEandfrequencies ofCD4+/IL-13+ T cells,aswell asdurationofdisease.Moreover,adecrease inFEV1,FE V 1/FVCwasobservedin
relation to the severity of asthma.Changes in cytokine proﬁle in CD8+ subpopulation didn’t depend on the severity of the disease.
Conclusions. Increased production of IL-4 and IL-13 in both CD4+ and CD8+ T cells accompanied by decreased IFN-γ expression
in CD4+ T cells may be evidence that both lymphocyte subpopulations are implicated in the pathogenesis of asthma.Relationship
of CD4+/IL-13+ T cells with disease activity suggests that this lymphocyte subset may have a prominent role in childhood asthma.
1.Introduction
Allergic asthma is one of the most common diseases in
childhood which is caused by a combination of genetic
and environmental factors [1]. A number of studies have
shown the important role of activated memory CD4+ T
cells as the main producer of Th2 cytokines in asthma
and other atopic diseases [2, 3]. Th2 cytokines such as
IL-4 and IL-13 interact with resident lung cells, including
airway epithelium, myoﬁbroblast, and smooth muscle cells,
to induce the asthmatic phenotype [3]. These cytokines
are the cause of pathophysiological features of asthma
includingairway inﬂammation, mucus secretion, and airway
hyperresponsiveness. The production of Th2 cytokines was
originally ascribed to CD4+ T cells, but a number of studies
provided evidence that CD8+ T cells are able to secrete Th2
cytokines and are also essential for allergic inﬂammation
and airway sensitivity [4, 5]. Although most of the studies
on the activity of T cells cytokines in asthma revealed
upregulated expression of Th2 cytokinesat the site ofallergic
inﬂammation, as well as in circulating peripheral blood
T cells, a recent study suggested that Th1 cells secreting
IFN-γ might cause severe airway inﬂammation [4]. Regula-
tory T cells (Treg) may play a critical role in controlling the
development of asthma, as they can suppress a potentially
harmful immune response. There is evidence that the
number and function of two major subsets of Treg, namely,
CD4+CD25+Foxp3+ Tregs and IL-10 producing Tregs, are
impaired or altered in patients with atopic asthma compared
with healthy individuals [6].
Until now, only a few studies have directly identiﬁed
diﬀerent subsets of peripheral blood and airway T cells in
children with asthma, and more speciﬁcally with respect
to intracellular cytokines production, and the results are
conﬂicting [7–10].
The aim of this study was toassess diﬀerencesincytokine
proﬁle in peripheral CD4+ and CD8+ T cells between
children with asthma and healthy controls and to determine
whether increasing severity of asthma is related to cytokine
production.2 Clinical and Developmental Immunology
Table 1: Demographic and clinical characteristics of patients with asthma and healthy children.
Asthma Healthy controls
N 40 18
Age, years, mean ± SE 9.02 ±0.35 9.28 ± 0.75
Sex, n M: 27; F: 13 M: 10; F: 8
Duration of asthma,years, mean ± SE 5.46 ±0.54
Serum total IgE, IU/ml, mean ± SE 312.95 ± 154.00
∗ 28.20 ± 2.23
Eosinophils, % (n, cells/μL), mean ± SE 7.2 ±0.8 (260.4± 10.4)
∗∗ 2.2±0.2 (137.3±6.2)
Positive skin prick test, n (%) 40 (100) 0
Dermatophagoides pteronyssinus 37 (92.5)
Dermatophagoides farinae 38 (95)
Grass pollens 21 (53)
Tree pollens 12 (30)
Weed pollens 15 (38)
Moulds 10 (25)
Feather 4 (10)
Cat 8 (20)
Dog 2 (5)
Total SPT wheal size, mm, mean ± SE 21.9 ±5.6
Current inhaled steroid use, n (%) 30 (75)
Lung function assessed, n (%) 35 (87.5%) 15 (83.3%)
FEV1%p r e d i c t e d 8 4 .3 ±2.06
# 96.4 ±2.047
FVC% predicted 83.3 ±1.95# 91.71 ± 1.41
FEV1%F V C 8 7 .47 ±1.63
# 91.97 ± 1.60
MEF25%p r e d i c t e d 8 5 .85 ±4.40# 95.85 ± 4.50
All P-values from Mann-Whitney U-test
∗P<. 01
∗∗P<. 001
#P<. 00001.
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Figure 1: Flow cytometric expression of CD69 (activation marker) on CD3+ T cells before (B) and after polyclonal stimulation (S) of one
patient with mild asthma (male, age 9.8yrs).
2.MaterialandMethods
The study group comprised of 40 children (aged 5.2 to 15.8
years; mean age 9.2 ± 0.35 years) with allergic asthma, of
whom 10 had intermittent, 14 mild, 12 moderate, and 4 had
severe persistent asthma. The diagnosis of asthma and the
assessment ofseverityweredoneaccordingtotheGINA2002
criteria [11]. All children had a history of recurrent episodes
of airway obstruction. Children above 6 years of age under-
went spirometric assessment and presented reversibility ofClinical and Developmental Immunology 3
airway obstruction, as documented by positive response
to a bronchodilator of at least 12% increase of forced
expiratory volume in one second (FEV1). All children had
positive skin prick tests (SPT) to one or more allergens (SPT
was regarded as positive when mean diameter was at least
3mm). The degree of allergic sensitization was measured by
wheal size of skin prick tests. Thirty children with mild-to-
severe persistent asthma were treated with regularly inhaled
glucocorticoids (ICS), but with variable daily dose required
to control the symptoms (at the time of evaluation, daily
ICS dose ranged from 100 to 1000μg/day, mean daily dose:
311.0 ± 25.6). Duration of ICS treatment ranged from two
monthsto11years(mean4.5±0.6).Allchildrenwithasthma
were well controlled; children with exacerbations were
excluded from the study. Detailed data of asthma duration
and ICS treatment were obtained from medical records and
speciﬁc questionnaire. The control group consisted of 18
healthy children (aged 4.7 to 16.0 years; mean age 9.2 ± 0.7
years) with a negative history of allergic disease, normal level
of total serum IgE, and negative results of skin prick test to a
panel of aeroallergens (dust mite, mixed grass or tree pollen,
cat, and dog; Allergopharma, Reinbek, Germany). Children
included into the control group attended the outpatient
pediatric clinic for nonimmunological, noninﬂammatory
health problems and needed venous puncture.
The present study was approved by Ethics Committee
of the Medical University of Silesia in Katowice and written
informed consent was obtained from children’s parents.
Venous blood samples were obtained from each subject.
2.1. Total Serum IgE Level. Total serum IgE concentration
was determined with the sandwich method which uses anti-
IgE antibodies adsorbed on the microplates and a conjugate
of alkaline phosphatase labeled goat anti-IgE antibody. The
serum samples were incubated on microplates with anti-
IgE antibody conjugate. The complexes IgE-anti-IgE were
detected adding substrate p-nitrophenylphosphate (PNPP),
and chromatic product was measured with photometry at
405 nm (ELISA kits, Allergopharma).
2.2. Intracellular Cytokine Staining. Intracellular cytokine
staining before and after polyclonalstimulation was assessed.
Heparinized whole blood was diluted with RPMI (BioWhit-
taker) and 2% calf serum and after the addition of
25μl (25ng/ml) of phorbol 12-myristate 13-acetate (PMA;
Sigma), 20μl( 1 μg/ml) of ionomycin (Sigma), and 10μl
(2.5μM) of monensin (Sigma) incubated in a water bath
for 4h at 37◦C. Stimulated whole blood was distributed in
100μl aliquots into tubes containing 20μla n t i h u m a nC D 3 -
FITC and CD4-PerCp (Becton Dickinson), vortexed, and
incubated for 20min at room temperature in the dark. To ﬁx
cells, 100μl ofIntraPrep Reagent1 (DAKO)was added to the
samples followed by vortexing and incubation for 15min at
room temperature in the dark and washing with 2ml of cell-
wash solution. Simultaneous permeabilization of white cells
and lysis of red cells was then carried out by adding 100μl
IntraPrep Reagent 2 (DAKO) and incubation. Intracellular
staining procedure included addition of 20μlo fa n t i - I L - 2 ,
IL-4, IL-10,IL-13, IFN-γ,andTNF -αmonoclonalantibodies
or isotope control mouse antibodies conjugated with PE
(CoulterImmunotech).Theﬂowcytometricassessment with
FACScanﬂowcytometry (BectonDickinson) was performed
on the same day. Acquisition was gated on CD3+CD4+ and
CD3+CD8+ cells, and thenthepercentageofCD3+CD4+ and
CD3+CD8+ cells producing IL-2, IL-4, IL-10, IL-13, IFN-γ,
and TNF-α was determined on dot plots. Quadrants were
set based on isotope control. The acquisition was performed
both on samples stimulated with PMA and ionomycin,
and on nonstimulated samples, in order to estimate the
residual intracellular expression of the cytokines. Activation
of the cells was conﬁrmed by estimation of the CD69
expression, which was over 95% in all samples (Figure 1).
Acquisition and analysis were performed with Cell Quest
software package (Becton Dickinson).
2.3. Statistical Analyses. Statistical analyses were performed
using software package (Statistica, version 3.0) and data
presented as mean value ± SE. Comparisons between groups
were made with the Kruskal-Wallis test, followed by Mann-
Whitney U test. Correlations were calculated using the
Spearman rank test. Values of P<. 05 were considered as
statistically signiﬁcant.
3.Results
The demographics and background characteristics of the
study groups are shown in Table 1. Both groups were similar
with regard to age.
3.1. Comparison of Eosinophil Counts and Serum IgE Levels
between Children with Asthma and Control Group. The per-
centage as well as the count of peripheral blood eosinophils
was signiﬁcantly elevated in asthma children as compared
with control group (P<. 001). Total serum IgE levels were
signiﬁcantly higher in children with asthma than in controls
(P<. 01).
3.2. Frequencies of CD4+ and CD8+ T Cells Spontaneously
Producing IL-2, IL-4, IL-10, IL-13, IFN-γ,a n dT N F - α in
Children with Asthma and Control Group. Mean values
of frequencies of CD4+ and CD8+ T cell spontaneously
producing IL-2, IL-4, IL-10, IL-13, IFN-γ,a n dT N F - α are
shown in Table 2. Percentage proportions of CD4+ Tc e l l
staining positively for IL-2, IL-4, IL-10, IL-13, IFN-γ,a n d
TNF-α in unstimulated whole blood were similar in children
with asthma compared to healthy controls. Frequencies of
CD8+ T spontaneously producing IL-4 were signiﬁcantly
higher in children with asthma than in healthy controls
(P<. 05). No signiﬁcant diﬀerence in remaining cytokine
expression by unstimulated CD8+ T cells between asthma
and control was observed.
3.3.FrequenciesofCD4+ andCD8+ TC ellPr oducingIL -2,IL -
4, IL-10, IL-13, IFN-γ,a n dT N F - α after In Vitro Stimulation
with Phorbol 12-Myristate 13-Acetate and Ionomycin in4 Clinical and Developmental Immunology
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Figure 2: (a) Flow cytometry of the cytokine production values of IL-2, IL-4, IL-10, IL-13, INF-γ,a n dT N F - α in CD4+ and CD8+ T
subpopulations.Exampleof onepatient withmild asthmaandone control.(b) Plotsof CD4+ andCD8+ T cells producing various cytokines
before and after polyclonal stimulation of one patient with mild asthma (male, age 9.8yrs) and one control (male, age-9.5yrs). B-baseline,
spontaneous cytokine staining without stimulation (in the presence of monensin alone), S-cytokine staining with stimulation (unseparated
whole blood from asthma patients and healthy controls was stimulated for 4h with PMA and ionomycin, and production of IL-2, IL-4,
IL-10, IL-13, INF-γ,a n dT N F - α of CD4+ and CD8 T+cells was determined at the single cell levels by intracellular cytokine stainingand ﬂow
cytometry as described in Section 2).
AsthmaPatientsandControlGroup. Mean valuesoffrequen-
cies of CD4+ and CD8+ T cell producing IL-2, IL-4, IL-10,
IL-13, IFN-γ,a n dT N F - α after in vitro stimulation with
phorbol 12-myristate 13-acetate and ionomycin are shown
in Table 3. Frequencies of CD4+ and CD8+ T cells producing
IL-4, IL-13 after in vitro stimulation were signiﬁcantly
higher in asthma patients than in the control group (IL-
4: P<. 00001, P<. 00003 for CD4+ and CD8+ T cells, resp.,
IL-13: P< . 00001 for CD4+ and CD8+ T cells). In contrast,
frequencies of CD4+ producing IFN-γ were signiﬁcantly
reduced in children with asthma compared to healthy sub-
jects (P<. 0001).Frequenciesof CD4+ staining positively for
IL-2, IL-10, and TNF-α,a n dCD8+ T cells staining positively
for IL-2, IL-10, TNF-α,a n dI F N - γ after in vitro stimulation
with phorbol 12-myristate 13-acetate and ionomycin were
similar in both groups.
An example of ﬂow cytometry of the examined cytokine
production values in CD4+ and CD8+ T subpopulations for6 Clinical and Developmental Immunology
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Figure 3: Scatterplot showing relationship between disease duration, total serum IgE, cytokine production, lung function indices, and the
severity of asthma (degree of disease: 1-intermittent, 2-mild persistent, 3-moderate persistent, and 4-severe persistent asthma).Correlations
werecalculatedusingtheSpearmantest.(a)Durationofdiseasecorrelatedhighlysigniﬁcantlywithseverityofasthma(r = 0.56;P<. 00003).
(b) Positive correlation between total serum IgE and severity of asthma was revealed (r = 0.4; P<. 001). (c) A highly negative correlation
between severity of asthma and FEV1 was identiﬁed (r =− 0.72; P<. 000001).(d) There was a weak positive correlation between severity of
asthma and the percentage of CD4+/IL10+Clinical and Developmental Immunology 7
Table 2: Percentage of CD4+ and CD8+ T cells spontaneously producing IL-2, IL-4, IL-10, IL-13, IFN-γ,a n dT N F - α.
CD4+/IL-2+ CD4+/IL-4+ CD4+/IL-10+ CD4+/I L - 1 3 + CD4+/IFN-γ+ CD4+/TNF-α+
Asthma n = 40 2.75 ±0.17 3.45 ± 0.24 3.78 ±0.26 3.78 ±0.23 .0 ±0.18 2.92 ± 0.15
Controls n = 18 3.11 ±0.31 2.83 ± 0.23 4.58 ±0.71 3.33 ±0.22 2.5 ±0.26 3.0 ± 0.35
CD8+/IL-2+ CD8+/IL-4+ CD8+/IL-10+ CD8+/IL-13+ CD8+/IFN-γ+ CD8+/TNF-α+
Asthma n = 40 3.4 ±0.21 3.45 ± 0.19
∗ 3.73 ±0.31 4.4 ±0.34 3.1 ±0.19 3.53 ± 0.26
Controls n = 18 3.58 ±0.36 2.75 ± 0.13 4.0 ±0.48 3.42 ±0.19 3.08 ±0.43 .0 ± 0.28
P-values from Mann-Whitney U-test
∗P<. 05
Data as shown as mean ± SE.
Table 3: Percentage of CD4+ T cells and CD8+ T cells producing IL-2, IL-4, IL-10, IL-13, IFN-γ,a n dT N F - α after in vitro activation with
phorbol 12-myristate-13-acetate and ionomycin.
CD4+/IL-2+ CD4+/IL-4+ CD4+/IL-10+ CD4+/IL-13+ CD4+/IFN-γ+ CD4+/TNF-α+
Asthma n = 40 7.78 ± 0.41 9.10 ±0.34
∗ 8.73 ±0.55 13.1 ±0.39
∗ 7.83 ± 0.43
∗∗ 7.73 ± 0.36
Controls n = 18 9.11 ± 0.56 6.17 ±0.39 9.25 ±0.69 7.83 ± 0.49 11.67 ±0.58 7.22 ± 0.42
CD8+/IL-2+ CD8+/IL-4+ CD8+/IL-10+ CD8+/IL-13+ CD8+/IFN-γ+ CD8+/TNF-α+
Asthma n = 40 8.08 ± 0.47 8.80 ±0.28$ 8.9 ±0.51 3 .00± 0.38
∗ 7.65 ±0.48 7.75 ± 0.49
Controls n = 18 8.08 ± 0.47 6.08 ±0.40 8.67 ±0.63 7.58 ± 0.53 8.50 ±0.38 6.83 ± 0.44
P-values from Mann-Whitney U-test
∗P<. 00001,∗∗P<. 0001, $P<. 00003
Data as shown as mean ± SE.
patient with mild asthma and one control are shown in
Figure 2.
3.4. Frequencies of CD4+ and CD8+ TC e l lp r o d u c i n gI L -
2, IL-4, IL-10, IL-13, IFN-γ,a n dT N F - α before and after In
Vitro Stimulation with Phorbol 12-Myristate 13-Acetate and
Ionomycin in Patients with Diﬀerent Degree of Severity of
Asthma. Mean value of levels of cytokines in each group
asthmatic children are shown in Table 4. After separating the
patients according to the severity of disease (intermittent,
mild persistent, moderate persistent, and severe persistent
asthma) and then comparing the four groups, there was a
signiﬁcant increase in frequencies of CD4+ T cells producing
IL-13 following stimulation in children with severe asthma
compared to those with intermittent asthma (P<. 04). Also,
in the group with severe asthma frequencies of polyclonaly
stimulated CD4+ T cells producing IL-10 tended to be
higher compared to all three remaining subgroups, but the
diﬀerence did not reach statistical signiﬁcance (P>. 07).
Additionally, frequencies of CD4+ T cells spontaneously
producing IL-10 were signiﬁcantly higher in severe than in
moderate persistent asthma (P<. 05). Remaining cytokines
were similar in the subgroups.
3.5. Association between Duration of Asthma, Total Serum
IgE, SPT, Cytokine Production, Lung Function Indices, Age
of Patients, and Asthma Severity. Severity of asthma was
positivelycorrelatedwithdurationofasthmaaswellasserum
IgE (r = 0.56; P<. 00003 and r = 0.4; P<. 001, resp.), but
inversely with spirometric parameters such as FEV1(forced
expiratory volume in one second), FEV1/FVC , (FEV1%
forced vital capacity ), and MEF25 (maximal expiratory ﬂow
at 25% FVC) (r =− 0.72; P<. 000001, r =− 0.56; P<. 009,
r =− 0.68; P<. 00001, resp.) (Figures 3(a), 3(b),a n d3(c)).
Moreover, severity of disease was positively correlated with
the percentage of CD4+ T cells expressing IL-10 and IL-13 in
response to PMA and ionomycin (r = 0.32, P<. 04, r = 0.4,
P<. 008, resp.) (Figures 3(d),a n d3(e)). No correlation was
found between severity of asthma and age of children as well
asdegreeofallergicsensitizationexpressedastotalSPTwheal
size (data not shown).
3.6. Relation between Cytokine Expression and Duration of
Asthma. FrequenciesofCD4+ TcellsproducingIL-10aswell
as CD4+ T cells producing IL-13 was positively correlated
with the duration of asthma (r = 0.44, P<. 004 and r = 0.4,
P<. 01, resp.) (Figures 4(a),a n d4(b)).
3.7. Relation between Dose and Duration of ICS Treatment
and Cytokine Expression. No signiﬁcant correlation between
doseofICSaswell asdurationofICStreatment and cytokine
expression in peripheral CD4+ and CD8+ T cells was found
(data not shown).
4.Discussion
Using ﬂow cytometric assay of the whole blood from
children with asthma, we demonstrated signiﬁcantly higher
frequencies of both CD4+ and CD8+T cells expressing
IL-4 and IL-13 compared with blood obtained from healthy,
nonatopic children. Similarly to other reports, the excessive
Th2 production by polyclonally stimulated T cells was
accompanied by signiﬁcantly decreased IFN-γ productionin
patients with asthma as compared to age-matched healthy
controls [12, 13]. In this study, we also found higher
frequencies of CD8+ T cells spontaneously producing IL-48 Clinical and Developmental Immunology
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Figure 4: Scatterplot showing relationship between asthma duration and cytokine proﬁle of peripheral blood T cells in asthmatic patients.
(a) A good positive correlation was identiﬁed between percentages of CD4+/IL-10+ followingstimulation and duration of asthma (r = 0.44,
P<. 004).(b) A good positive correlation was identiﬁed between percentages ofCD4+/IL-13+ followingstimulationand duration of asthma
(r = 0.4, P<. 01). Correlations were calculated using the Spearman test.
in children with asthma, which conﬁrms previous ﬁndings
from adult asthma patients, demonstrating increased levels
of IL-4 in resting peripheral blood CD8+ T cells [14]. In the
presentstudy, we providedevidencethatincreased frequency
of CD4+/IL-13+,b u tn o tC D 4 +/IL-4+ T cells was correlated
with severity of asthma and these ﬁndings further suggest
that IL-13 is a principal cytokine responsible for asthmatic
symptoms.
Increasingly, more evidence indicates that IL-13 plays a
crucial role in the Th2 driven immunopathology and airway
hyperresponsiveness seen in asthma [15–18]. IL-13 alone
may mediate the main pathophysiological features of the
disease,namely,mucushypersecretion, subepithelialﬁbrosis,
and bronchial hyperresponsiveness [15]. Moreover, some
reports suggested that an increased IL-4 cytokine response
is not necessarily a reﬂection of asthma activity but rather of
the atopic state per se [19].
An increased expression of IL-13 in bronchial specimens,
bronchoalveolar lavage ﬂuid and cells, induced sputum, as
well as in serum and allergen- or polyclonal-stimulated
peripheral blood mononuclear cells from adult asthmatic
patients have been reported by several authors [16–18,
20, 21]. Moreover, IL-13 levels in the airways correlated
w i t hd i s e a s es e v e r i t yi nc h i l d r e na n dd e g r e eo fa i r w a y
hyperresponsiveness in adult asthma subjects, which may
correspond well with our ﬁndings [16, 17].
Our study diﬀers from the recent study by Ant´ unez et al.
who reported that IL-4 and IL-13 production by circulating
CD4+ and CD8+ T cells in response to phorbol 12-myristate
13-acetate and ionomycin was not signiﬁcantly diﬀerent in
15 children with mild asthma compared to healthy controls
[9]. In the present study, a larger group of subject with dif-
ferent degree of disease was investigated, but no diﬀerence in
IL-4 levels between intermittent, mild, moderate and severe
persistent asthma was observed. In contrast, an increase in
IL-13 in CD4+ T cells in severe asthma was revealed, though
it was only signiﬁcant as compared to intermittent asthma.
An explanation for diﬀerences between our and Antunez
study may be that asthma is heterogeneous disease. The
recent ﬁnding suggests that asthma can be divided into at
least two distinct molecular phenotypes deﬁned by degree of
Th2 inﬂammation, even in atopic subjects [22]
Similarly to other studies, a decrease in IFN-γ in our
group of patients with asthma was conﬁned to the CD4+
population of T cells, while CD8+ T cells did not show
a signiﬁcant decrease in IFN-γ [12]. It is believed that a
defect in IFN-γ secretion following polyclonal stimulation
is a general feature of atopic disease, and the role of IFN-
γ in the pathogenesis of asthma is more complex. Indeed,
in some studies, a signiﬁcant decrease in IFN-γ in children
and adults with severe asthma was found [23, 24]w h e r e a s
a recent study in adult subjects suggest that the severity of
asthma is associated with an increase in IFN-γ produced by
CD8+ Tc e l l s[ 25].
In our study, we could not ﬁnd any diﬀerences regarding
IL-10 production by T cells between children with asthma
and healthy controls, which is in line with the ﬁndings from
other studies [9], but a trend towards higher cytokine level
in the CD4+ T in children with severe asthma was observed.
Unexpectedly, we also showed a weak correlation between
IL-10 producing CD4+ T cells and the severity of asthma
which may suggest that the expression of this cytokine is
associated with aggravated allergic inﬂammation.
IL-10 is known to be secreted by many T cell sub-
sets including CD8+ and CD4+ T cells. Unique popula-
tions of CD4+ T cells with regulatory properties; namely,
CD4+CD25+FoxP3+ Treg cells and IL-10 producing Tregs
have been identiﬁed [6]. Tregs distinct from conventionalClinical and Developmental Immunology 9
Table 4: Percentage of CD4+ T cells and CD8+ T cells producing IL-2, IL-4, IL-10, IL-13, INF-γ,a n dT N F - α before and after in vitro
activation with phorbol 12-myristate-13-acetate and ionomycin in the four groups of asthmatics (1-intermittent, 2-mild persistent, 3-
moderate persistent, and 4-severe persistent asthma). In parenthesis, the frequencies of spontaneous cytokine staining (in the presence
of monensinalone) are presented.
Subgroups of asthma patients
persistent asthma
1-intermittent
n-10
2-mild
n-14
3-moderate
n-12
4-severe
n-4
CD4+/IL-2+ 7.5 ±0.9
(3.2 ±0.5)
7.5 ±0.6
(2.8 ±0.3)
9.1 ± 0.6
(2.3 ± 0.2)
6.9 ±0.5
(3.0 ±0.0)
CD4+/IL-4+ 9.1 ±1.1
(3.1 ±0.3)
9.1 ±0.4
(3.9 ±0.5)
9.6 ± 0.4
(3.0 ± 0.4)
7.0 ±0.41
(3.5 ±0.3)
CD4+/IL-10+ 7.1 ±0.9
(5.0 ±0.9)
8.9 ±0.9
(3.5 ±0.5)
8.5 ± 0.8
(3.0 ±0.4)
∗∗
11.2 ±0.2
(5.2 ±0.2)
CD4+/IL-13+ 11.5 ±0.9
(4.0 ±0.9)
13.0 ± 0.7
(3.5 ±0.3)
13.3 ±0.5
(3.4 ± 0.3)
15.2 ±0.2
∗
(5.2 ±0.2)
CD4+/IFN-γ+ 6.8 ±1.3
(3.3 ±0.5)
7.9 ±0.7
(3.0 ±0.3)
7.0 ± 0.5
(2.7 ± 0.2)
7.2 ±0.2
(3.0 ±0.0)
CD4+/TNF-α+ 8.0 ±0.9
(3.1 ±0.3)
8.5 ±0.5
(3.1 ±0.2)
6.5 ± 0.6
(2.9 ± 0.1)
8.0 ±0.4
(3.7 ±0.0)
CD8+/IL-2+ 7.5 ±1.0
(3.5 ±0.5)
8.5 ±0.8
(3.5 ±0.4)
7.3 ± 0.7
(3.1 ± 0.2)
9.2 ±0.2
(4.7 ±0.2)
CD8+/IL-4+ 8.2 ±0.9
(3.7 ±0.5)
8.6 ±0.4
(3.6 ±0.3)
9.3 ± 0.4
(3.0 ± 0.2)
8.2 ±0.2
(3.5 ±0.2)
CD8+/IL-10+ 7.5 ±0.8
(3.8 ±0.5)
9.7 ±1.0
(4.3 ±0.6)
8.2 ± 0.6
(3.3 ± 0.4)
10.0 ±0.0
(2.2 ±0.2)
CD8+/IL-13+ 12.8 ±0.9
(4.4 ±0.6)
13.4 ± 0.7
(4.9 ±0.7)
12.2 ±0.5
(3.4 ± 0.3)
14.0 ±0.5
(5.2 ±0.7)
CD8+/IFN-γ+ 7.14 ±1.0
(3.5 ±0.9)
8.6 ±0.91
(3.0 ±0.3)
7.1 ± 0.6
(2.9 ± 0.3)
6.0 ±0.0
(3.0 ±0.0)
CD8+/TNF-α+ 7.57 ±0.87
(3.7 ±0.6)
9.1 ±0.9
#
(3.4 ±0.4)
6.3 ± 0.6
(3.6 ± 0.4)
7.2 ±0.2
(3.0 ±0.0)
∗P<. 04 severe persistent asthma versus intermittent asthma.
∗∗P<. 05 severe persistent asthma versus moderate persistent asthma.
P-values from Mann-Whitney U-test.
Data as shown as mean ± SE.
CD4+ T cells characterized by the expression of CD25 and
intracellular FoxP3 protein were not assessed in the current
study. On the other hand, IL-10 is a potent inhibitor of
monocyte/macrophagefunction,suppressingtheproduction
of many proinﬂammatory cytokines and both Th1 and
Th2 cell activation. There is increasing evidence that IL-
10 secretion, in particular by Treg, may be defective in
patients with asthma [26]. It was shown that T cells from
children with asthma produce less IL-10 mRNA, and severe
asthma in adult is associated with reduced frequency of
IL-10 producing CD4+ T cells [27, 28]. In addition, lower
concentrations of IL-10 in bronchoalveolar lavage (BAL)
ﬂuid or in induced sputum were found in subjects with
asthma [29, 30]. On the contrary, other studies reported an
increase in IL-10 levels in the serum or in the bronchoalve-
olar lavage ﬂuid, [20, 31]a sw e l la sh i g h e rf r e q u e n c yo f
circulatingIL-10—producingTcellsinasthmaticscompared
with healthy subjects [32]. Moreover, paediatric patients
with moderate to severe bronchial asthma had increased
IL-10 mRNA expression in CD4+ T cells compared to those
subjects with milder disease [33]. IL-10 may also promote
airway hyperresponsiveness and eosinophilia in models of
allergy [34].
Our results also revealed that the severity of asthma was
associated with increased total IgE levels, but not with the
degree of sensitisation (i.e., skin prick test reactivity to a
panel of allergens).Moreover, a decrease in FEV1, FEV1/FVC,
and MEF-25 was observed in relation to the severity of
asthma. Although most of the children in our study were
regularly treated with ICS, we did not see a signiﬁcant eﬀect
ofdoseordurationofICStreatment ontheproﬁle ofstudied
cytokines. On the other hand an increase in IL-10 and
IL-13 in the CD4+,b u tn o ti nt h eC D 8 + T cells, was related
with duration of asthma. In our study, although changes
in cytokine proﬁle secreted by CD8+ T cells in asthmatic
subjects were found, they were independent of the severity
of disease.
A possible limitation of our study is that it included
children with a wide range of age, which although similar
to that of the control group may bias the assessment of10 Clinical and Developmental Immunology
severity of asthma. Moreover, a cross-sectional design of
our study limits the validity of our interpretation of the
possible eﬀect of ICS therapy on examined immunological
parameters. Several studies have demonstrated that inhaled
glucocorticoidtreatment decrease Th2 cytokineand increase
IL-10 mRNA and IFN-γ expression in peripheral blood T
cells in moderate and severe asthmatic patients [10, 35].
The small numbers of the subjects with severe lung disease
may also be a drawback of this study; nevertheless, some
diﬀerencesbetween severe asthma and other subgroups were
found.
In conclusion, this study demonstrated dominant type
2-cytokine expressions in peripheral blood T cells in atopic
asthma. Increased production of IL-4 and IL-13 in both
CD4+ and CD8+ T cells accompanied by decreased IFN-
γ expression in CD4+ T cells may be evidence that both
lymphocyte subpopulations are implicated in the pathogen-
esis of asthma. In our study, although changes in cytokine
proﬁle in CD8+ T were found, they did not depend on the
severity of the disease. Relationship of CD4+/IL-13+ T cells
withdiseaseactivitysuggeststhatthislymphocytesubsetmay
have a prominent role in childhood asthma.
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